바이오모아 (BioMoa) — ADC · Antibody

9268프로그램 35FDA 승인

0오늘 방문

738누적 방문

8122갱신 대기 S–CData Tier S/A/B차세대 1068HER2 breast 5456Antibody 2744CGT →Psoriasis →NSCLC 35FDA 승인

피드 Data Tier 차세대

최근 활동

RSS →

AntibodystaleAgendiaApproved

trastuzumab (Herceptin, Dose dense AC followed by T + trastuzumab + pertuzumab)

Breast Cancer · Breast Cancer

#BreastCancer#Antibody#Approved#항체#면역항체+2

임상시험 1상태 ACTIVE

AntibodystaleAmgenPhase 2

ABX-EGF (Panitumumab, Panitumumab (ABX-EGF))

Colorectal Cancer; Non-Small Cell Lung Cancer · Colorectal Cancer

#ColorectalCancer#Antibody#Phase2#항체#면역항체+3

임상시험 1상태 ACTIVE

AntibodystaleChangchun GeneScience Pharmaceu…Phase 1

Gentulizumab (Gentulizumab)

Solid Tumor; Non-Hodgkin Lymphoma · Solid Tumor

#SolidTumor#Antibody#Phase1#항체#면역항체+3

임상시험 1상태 DISCONTINUED

AntibodyTae Won KimPhase 2

atezolizumab (Tecentriq, Aatezolizumab plus Bevacizumab)

Hepatocellular Carcinoma · Hepatocellular Carcinoma

#HepatocellularCarcinoma#Antibody#Phase2#항체#면역항체+3

임상시험 1상태 RECRUITING

AntibodystaleEli LillyPhase 2

cetuximab (CTX, cetuximab, cetuximab (CTX) or nimotuzumab (NTZ))

Nasopharyngeal Carcinoma · Nasopharyngeal Carcinoma

#NasopharyngealCarcinoma#Antibody#Phase2#항체#면역항체+2

임상시험 1상태 ACTIVE

AntibodystaleJanssenPhase 2

Infliximab and Basiliximab (Infliximab and Basiliximab)

Graft Versus Host Disease; Steroid Refractory GVHD · FRα

#FR#Antibody#Phase2#항체#면역항체+4

효능 ORR 10%임상시험 1상태 DISCONTINUED

AntibodystaleVanda PharmaceuticalsPhase 2

Imsidolimab (Imsidolimab)

Ichthyosis · Ichthyosis

#Ichthyosis#Antibody#Phase2#항체#면역항체+2

임상시험 1상태 DISCONTINUED

AntibodystaleOslo University HospitalPhase 2

Radiotherapy, rituximab and DC (Radiotherapy, rituximab and DC)

Follicular Lymphoma · Follicular Lymphoma

#FollicularLymphoma#Antibody#Phase2#항체#면역항체+2

임상시험 1상태 ACTIVE

AntibodystaleRochePhase 1

Bevacizumab and Sunitinib (Bevacizumab and Sunitinib)

Metastatic Renal Cell Carcinoma; Kidney Cancer · Metastatic Renal Cell Carcinoma

#MetastaticRenalCellCarcinoma#Antibody#Phase1#항체#면역항체+3

임상시험 1상태 ACTIVE

AntibodystaleEli LillyPhase 2

cetuximab, cisplatin, capecitabine (cetuximab, cisplatin, capecitabine)

Gastric Cancer · Gastric Cancer

#GastricCancer#Antibody#Phase2#항체#면역항체+2

임상시험 1상태 ACTIVE

AntibodystaleHenan Cancer HospitalPhase 2

trastuzumab (Herceptin, SHR-1210 Combined With Trastuzumab , Oxaliplatin and Capecitabine)

Gastric Cancer · Gastric Cancer

#GastricCancer#Antibody#Phase2#항체#면역항체+2

임상시험 1상태 RECRUITING

AntibodystaleUniversity of Southern Californ…Phase 2

Fragmin, 5-Fluorouracil, Folinic Acid, irinotecan, bevacizumab (Fragmin, 5-Fluorouracil, Folinic Acid, irinotecan, bevacizumab)

Colorectal Cancer · FRα

#FR#Antibody#Phase2#항체#면역항체+3

임상시험 1상태 DISCONTINUED

AntibodystaleWeill Medical College of Cornel…Phase 3

Higher Dose of Rituximab (Higher Dose of Rituximab)

Immune Thrombocytopenic Purpura · Immune Thrombocytopenic Purpura

#ImmuneThrombocytopenicPurpura#Antibody#Phase3#항체#면역항체+2

임상시험 1상태 ACTIVE

AntibodystaleBiocon Biologics UK LtdPhase 3

Bmab1200 (Bmab1200)

Moderate to Severe Chronic Plaque Psoriasis · Moderate to Severe Chronic Plaque Psoria

#ModeratetoSevereChronicPlaquePso#Antibody#Phase3#항체#면역항체+2

임상시험 1상태 ACTIVE

AntibodystalePfizerPhase 3

gemtuzumab ozogamycin (gemtuzumab ozogamycin)

Acute Myeloid Leukemia · Acute Myeloid Leukemia

#AcuteMyeloidLeukemia#Antibody#Phase3#항체#면역항체+2

임상시험 1상태 ACTIVE

AntibodystaleBristol Myers SquibbPhase 1

ipilimumab (Yervoy®, Yervoy® (ipilimumab))

Melanoma (Excluding Uveal Melanoma); Cervical Carcinoma · HER2

#HER2#Antibody#Phase1#항체#면역항체+4

임상시험 1상태 ACTIVE

AntibodystaleXencor, Inc.Phase 1

XmAb®23104 (XmAb®23104)

Melanoma (Excluding Uveal Melanoma); Cervical Carcinoma · HER2

#HER2#Antibody#Phase1#항체#면역항체+4

임상시험 1상태 ACTIVE

AntibodystalePartner Therapeutics, Inc.Phase 2

MCLA-128 (zenocutuzumab, zenocutuzumab (MCLA-128))

Solid Tumours Harboring NRG1 Fusion; NSCLC Harboring NRG1 Fusion · Solid Tumours Harboring NRG1 Fusion

#SolidTumoursHarboringNRG1Fusion#Antibody#Phase2#항체#면역항체+3

임상시험 1상태 RECRUITING

AntibodystaleChugai PharmaceuticalPhase 1

Tocilicumab (Tocilicumab)

Hepatocellular Carcinoma (HCC) · Hepatocellular Carcinoma (HCC)

#HepatocellularCarcinomaHCC#Antibody#Phase1#항체#면역항체+2

임상시험 1상태 RECRUITING

AntibodystaleXencor, Inc.Phase 1

XmAb808 (XmAb808)

Ovarian Cancer · Ovarian Cancer

#OvarianCancer#Antibody#Phase1#항체#면역항체+2

임상시험 1상태 RECRUITING

AntibodystaleWigen Biomedicine Technology (S…Phase 2

WJB001 Capsules+Bevacizumab (WJB001 Capsules+Bevacizumab)

Advanced Solid Tumor · Advanced Solid Tumor

#AdvancedSolidTumor#Antibody#Phase2#항체#면역항체+2

임상시험 1상태 RECRUITING

AntibodystaleWigen Biomedicine Technology (S…Phase 2

WJB001 Capsules+Paclitaxel+carboplatin+JS207/Toripalimab (WJB001 Capsules+Paclitaxel+carboplatin+JS207/Toripalimab)

Advanced Solid Tumor · Advanced Solid Tumor

#AdvancedSolidTumor#Antibody#Phase2#항체#면역항체+2

임상시험 1상태 RECRUITING

AntibodystaleSichuan Cancer Hospital and Res…Phase 2

cadonilimab+paclitaxel/albumin-bound paclitaxel+carboplatin (cadonilimab+paclitaxel/albumin-bound paclitaxel+carboplatin)

NSCLC · NSCLC

#NSCLC#Antibody#Phase2#항체#면역항체+2

임상시험 1상태 RECRUITING

AntibodystaleMacroGenicsPhase 2

Flotetuzumab 3 ng/kg/day, 4 days on and 3 days off (Flotetuzumab 3 ng/kg/day, 4 days on and 3 days off)

AML · AML

#AML#Antibody#Phase2#항체#면역항체+2

효능 ORR 0%임상시험 1상태 DISCONTINUED

AntibodystaleMacroGenicsPhase 2

Flotetuzumab 10 ng/kg/day, 4 days on and 3 days off (Flotetuzumab 10 ng/kg/day, 4 days on and 3 days off)

AML · AML

#AML#Antibody#Phase2#항체#면역항체+2

효능 ORR 0%임상시험 1상태 DISCONTINUED

87 / 167 페이지

← 이전 다음 →

전체 9,268개 프로그램 보기

갱신 기록 없음 · 14일 주기 · 방문 0 / 738

함께 비교하는 진짜 ADC · Antibody · CGT 데이터

추천 비교

최근 활동

빠른 검색 · 이슈 태그

trastuzumab (Herceptin, Dose dense AC followed by T + trastuzumab + pertuzumab)

ABX-EGF (Panitumumab, Panitumumab (ABX-EGF))

Gentulizumab (Gentulizumab)

atezolizumab (Tecentriq, Aatezolizumab plus Bevacizumab)

cetuximab (CTX, cetuximab, cetuximab (CTX) or nimotuzumab (NTZ))

Infliximab and Basiliximab (Infliximab and Basiliximab)

Imsidolimab (Imsidolimab)

Radiotherapy, rituximab and DC (Radiotherapy, rituximab and DC)

Bevacizumab and Sunitinib (Bevacizumab and Sunitinib)

cetuximab, cisplatin, capecitabine (cetuximab, cisplatin, capecitabine)

trastuzumab (Herceptin, SHR-1210 Combined With Trastuzumab , Oxaliplatin and Capecitabine)

Fragmin, 5-Fluorouracil, Folinic Acid, irinotecan, bevacizumab (Fragmin, 5-Fluorouracil, Folinic Acid, irinotecan, bevacizumab)

Higher Dose of Rituximab (Higher Dose of Rituximab)

Bmab1200 (Bmab1200)

gemtuzumab ozogamycin (gemtuzumab ozogamycin)

ipilimumab (Yervoy®, Yervoy® (ipilimumab))

XmAb®23104 (XmAb®23104)

MCLA-128 (zenocutuzumab, zenocutuzumab (MCLA-128))

Tocilicumab (Tocilicumab)

XmAb808 (XmAb808)

WJB001 Capsules+Bevacizumab (WJB001 Capsules+Bevacizumab)

WJB001 Capsules+Paclitaxel+carboplatin+JS207/Toripalimab (WJB001 Capsules+Paclitaxel+carboplatin+JS207/Toripalimab)

cadonilimab+paclitaxel/albumin-bound paclitaxel+carboplatin (cadonilimab+paclitaxel/albumin-bound paclitaxel+carboplatin)

Flotetuzumab 3 ng/kg/day, 4 days on and 3 days off (Flotetuzumab 3 ng/kg/day, 4 days on and 3 days off)

Flotetuzumab 10 ng/kg/day, 4 days on and 3 days off (Flotetuzumab 10 ng/kg/day, 4 days on and 3 days off)

함께 비교하는 진짜 ADC · Antibody · CGT 데이터

추천 비교

최근 활동

빠른 검색 · 이슈 태그

실시간 이슈 · 검색

trastuzumab (Herceptin, Dose dense AC followed by T + trastuzumab + pertuzumab)

ABX-EGF (Panitumumab, Panitumumab (ABX-EGF))

Gentulizumab (Gentulizumab)

atezolizumab (Tecentriq, Aatezolizumab plus Bevacizumab)

cetuximab (CTX, cetuximab, cetuximab (CTX) or nimotuzumab (NTZ))

Infliximab and Basiliximab (Infliximab and Basiliximab)

Imsidolimab (Imsidolimab)

Radiotherapy, rituximab and DC (Radiotherapy, rituximab and DC)

Bevacizumab and Sunitinib (Bevacizumab and Sunitinib)

cetuximab, cisplatin, capecitabine (cetuximab, cisplatin, capecitabine)

trastuzumab (Herceptin, SHR-1210 Combined With Trastuzumab , Oxaliplatin and Capecitabine)

Fragmin, 5-Fluorouracil, Folinic Acid, irinotecan, bevacizumab (Fragmin, 5-Fluorouracil, Folinic Acid, irinotecan, bevacizumab)

Higher Dose of Rituximab (Higher Dose of Rituximab)

Bmab1200 (Bmab1200)

gemtuzumab ozogamycin (gemtuzumab ozogamycin)

ipilimumab (Yervoy®, Yervoy® (ipilimumab))

XmAb®23104 (XmAb®23104)

MCLA-128 (zenocutuzumab, zenocutuzumab (MCLA-128))

Tocilicumab (Tocilicumab)

XmAb808 (XmAb808)

WJB001 Capsules+Bevacizumab (WJB001 Capsules+Bevacizumab)

WJB001 Capsules+Paclitaxel+carboplatin+JS207/Toripalimab (WJB001 Capsules+Paclitaxel+carboplatin+JS207/Toripalimab)

cadonilimab+paclitaxel/albumin-bound paclitaxel+carboplatin (cadonilimab+paclitaxel/albumin-bound paclitaxel+carboplatin)

Flotetuzumab 3 ng/kg/day, 4 days on and 3 days off (Flotetuzumab 3 ng/kg/day, 4 days on and 3 days off)

Flotetuzumab 10 ng/kg/day, 4 days on and 3 days off (Flotetuzumab 10 ng/kg/day, 4 days on and 3 days off)

함께 비교하는 진짜 ADC · Antibody · CGT 데이터

추천 비교

최근 활동

빠른 검색 · 이슈 태그

실시간 이슈 · 검색

trastuzumab (Herceptin, Dose dense AC followed by T + trastuzumab + pertuzumab)

ABX-EGF (Panitumumab, Panitumumab (ABX-EGF))

Gentulizumab (Gentulizumab)

atezolizumab (Tecentriq, Aatezolizumab plus Bevacizumab)

cetuximab (CTX, cetuximab, cetuximab (CTX) or nimotuzumab (NTZ))

Infliximab and Basiliximab (Infliximab and Basiliximab)

Imsidolimab (Imsidolimab)

Radiotherapy, rituximab and DC (Radiotherapy, rituximab and DC)

Bevacizumab and Sunitinib (Bevacizumab and Sunitinib)

cetuximab, cisplatin, capecitabine (cetuximab, cisplatin, capecitabine)

trastuzumab (Herceptin, SHR-1210 Combined With Trastuzumab , Oxaliplatin and Capecitabine)

Fragmin, 5-Fluorouracil, Folinic Acid, irinotecan, bevacizumab (Fragmin, 5-Fluorouracil, Folinic Acid, irinotecan, bevacizumab)

Higher Dose of Rituximab (Higher Dose of Rituximab)

Bmab1200 (Bmab1200)

gemtuzumab ozogamycin (gemtuzumab ozogamycin)

ipilimumab (Yervoy®, Yervoy® (ipilimumab))